Skip to content

Δ9-Tetrahydrocannabinol

THC, Delta-9-THC, Δ9-THC, Dronabinol, Delta-9-tetrahydrocannabinol, Marinol, Syndros

CAS 1972-08-3Drug of abuseCannabinoid
Educational reference only — not for casework interpretation. Verify every value against primary sources.

Text review: Needs verification · 0 of 9 values verified

Overview

Category
Drug of abuse
Class
Cannabinoid
Mechanism
The main psychoactive constituent of cannabis. It is highly lipophilic and acts mainly as a partial agonist at the cannabinoid receptors of the brain. In the liver it is oxidised, chiefly by CYP2C9, with CYP2C19 a minor contributor, to 11-hydroxy-THC, which is itself pharmacologically active; further oxidation by CYP enzymes and alcohol and aldehyde dehydrogenases gives 11-nor-9-carboxy-THC (THC-COOH), the main circulating metabolite. Oral use gives relatively more 11-hydroxy-THC than smoking because of first-pass hepatic metabolism.

Concentrations

Needs verification

0 of 5 values verified

0 of 5 values verified
SpecimenTherapeuticToxicLethal
Blood (peripheral)aNot yet addedNot yet addedNot yet added
UrinebNot applicablebNot yet addedNot yet added

Notes

  • aBlood (peripheral) — Dronabinol is marketed as a licensed medicine, so a therapeutic entry is kept, but a recreational-use blood concentration is not a therapeutic range. No agreed toxic or lethal blood concentration for THC is established in the sources read; overdose deaths from THC alone are rare. Blood concentration alone does not establish impairment.
  • bUrine — Urine is used to show past exposure (mainly THC-COOH, largely as the glucuronide), not impairment. Screening is judged against laboratory cut-offs, not toxic or lethal limits.

Detection windows

Needs verification
SpecimenWindow
Blood (peripheral)aNot yet added
UrinebNot yet added

Notes

  • aBlood (peripheral) — THC in blood falls quickly after use; in frequent users it can remain detectable well after the last use.
  • bUrine — Window depends on frequency of use, route and the cut-off applied; multiple THC-COOH peaks are common in frequent users.

Metabolites

  • 11-Hydroxy-THC (11-OH-THC)ActivePharmacologically active. The postmortem redistribution study read describes it as equipotent to THC; no potency comparison is made in the metabolism paper read. Formed mainly by CYP2C9, with CYP2C19 a minor contributor that may matter in some people or if CYP2C9 activity is impaired.
  • 11-Nor-9-carboxy-THC (THC-COOH)Not activeNon-psychoactive; the main circulating metabolite and the usual urine target. Excreted largely as a glucuronide conjugate.

Recommended specimens

Collection and storage

Needs verification

Blood (peripheral)

Container
Plastic screw-cap container, as the guideline specifies for peripheral blood, with fluoride preservative, filled completely and sealed
Preservative
Sodium fluoride
Storage temperature
Not yet added
Note
The guideline calls fluoride mandatory for peripheral blood, and the postmortem redistribution study read used paired cardiac and peripheral sodium fluoride tubes. No THC-specific container advice was found.

Urine

Container
Plastic screw-cap container without preservative
Preservative
None specified
Storage temperature
Not yet added
Note
The guideline and the UNODC kit both describe urine in a plastic container without preservative; UNODC says specimens should be refrigerated.

Analytical methods

  • Immunoassay screen of urine (cannabinoids)ScreeningPresumptive only. UNODC states that a positive immunoassay result requires confirmation with a more selective technique, and the urine cannabinoid study notes that frequent smokers can stay immunoassay positive long after stopping, so a positive screen shows exposure rather than recent use.
  • GC-MS for THC, 11-OH-THC and THC-COOH in bloodConfirmationPractise on the GC-MS simulatorMultidimensional GC-MS was used in the postmortem study read; sensitivity is needed because blood concentrations are low.
  • GC-MS quantification of THC and metabolitesQuantificationPractise on the GC-MS simulator

Interpretation notes

Blood concentration and impairment

Blood THC alone cannot establish impairment. Impairment models come from living volunteers and plasma, and chronic users can test positive well after last use, so a positive result does not show recent use.

Rapid fall in blood

Blood THC drops quickly after exposure, while THC-COOH persists longer. Timing of the sample relative to use matters more than for most drugs.

Postmortem redistribution

Central blood tends to read higher than peripheral blood, and the difference may grow with postmortem interval. In the small study read the effect was modest and only significant for THC-COOH, and the limited antemortem samples suggested postmortem values may overstate THC. Treat postmortem THC cautiously and prefer peripheral blood.

Urine

Urine shows exposure history, not impairment. The usual analyte is THC-COOH, mostly as the glucuronide, and results after oral use differ from smoked or vaporised use.

Putrefaction and storage

Putrefaction and long storage can create matrix interference that stops THC or its metabolites being quantified in some blood samples.

Sources

  1. [1]National Center for Biotechnology Information. PubChem compound record: Dronabinol (synonyms list, fetched via PubChem PUG REST). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/dronabinol/synonyms/TXT
  2. [2]Yabut KCB, Wen YW, Simon KT, Isoherranen N. CYP2C9, CYP3A and CYP2C19 metabolize Δ9-tetrahydrocannabinol to multiple metabolites but metabolism is affected by human liver fatty acid binding protein (FABP1). Biochemical Pharmacology. 2024;228:116191. (2024) https://pmc.ncbi.nlm.nih.gov/articles/PMC11410521/
  3. [3]Holland MG, Schwope DM, Stoppacher R, Gillen SB, Huestis MA. Postmortem redistribution of Δ9-tetrahydrocannabinol (THC), 11-hydroxy-THC (11-OH-THC), and 11-nor-9-carboxy-THC (THCCOOH). Forensic Science International. 2011;212(1-3):247-251. (2011) https://pmc.ncbi.nlm.nih.gov/articles/PMC3413259
  4. [4]Huestis MA, Sempio C, Newmeyer MN, Andersson M, Barnes AJ, Abulseoud OA, Blount BC, Schroeder J, Smith ML. Free and glucuronide urine cannabinoids after controlled smoked, vaporized and oral cannabis administration in frequent and occasional cannabis users. Journal of Analytical Toxicology. 2020. (2020), Introduction https://pmc.ncbi.nlm.nih.gov/articles/PMC7673603/
  5. [5]Dinis-Oliveira RJ, Vieira DN, Magalhães T. Guidelines for collection of biological samples for clinical and forensic toxicological analysis. Forensic Sciences Research. 2017;1(1):42-51. doi:10.1080/20961790.2016.1271098 (2017), Antemortem or post-mortem samples; Kits: containers, labelling and toxicological request form https://pmc.ncbi.nlm.nih.gov/articles/PMC6197137/
  6. [6]United Nations Office on Drugs and Crime. Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts (ST/NAR/45). New York: United Nations; 2011. (2011), 3.1. Evidence collection kits; Analytical strategy https://www.drugsandalcohol.ie/16876/1/UNODC_forensic_analys_of_drugs_facilitating_sexual_assault_and_other_criminal_acts.pdf
Text review
Needs verification
Values
0 of 9 values verified
Last reviewed
—
Note
No source read describes a cannabinoid-specific urine immunoassay or its cut-off; the entry rests on UNODC's general immunoassay statement and background in the Huestis paper. No THC-specific container advice was found, so general guideline advice is used.

Used in cases

Back to the referenceSpecimen collection guides